Keli Walbert
Patrimonio netto: - $ in data 31/07/2026
Patrimonio netto: - $ in data 31/07/2026
Keli Walbert is currently an Independent Director at Spruce Biosciences, Inc. since 2025.
Former positions include Independent Director at Apellis Pharmaceuticals, Inc. from 2025 to 2026, and Executive Vice President-US Commercial at Horizon Therapeutics Ltd. (Ireland) from 2019 to 2023.
Education includes graduate studies at Northwestern University and undergraduate studies at the University of Louisville.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 21/05/2026 | 0 ( -.--% ) | - $ | 31/07/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| SPRUCE BIOSCIENCES, INC. | Direttore/Membro del Consiglio | 11/12/2025 |
| Società | Posizione | Fine |
|---|---|---|
| APELLIS PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 14/05/2026 |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Corporate Officer/Principal | 01/01/2023 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics and drug delivery technologies to address chronic inflammatory diseases | Health Technology |
Horizon Therapeutics Ltd. (Ireland)
Horizon Therapeutics Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Discovers, develops and manufactures pharmaceuticals for autoimmune & inflammatory diseases | Health Technology |
Northwestern University
Northwestern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Louisville
University of Louisville Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Spruce Biosciences, Inc.
Spruce Biosciences, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale